Cefprozil: Difference between revisions

Cefprozil
Clinical data
Trade names	Cefzil
AHFS/Drugs.com	Monograph
MedlinePlus	a698022
License data	US FDA: Cefprozil;
Routes of; administration	Oral
ATC code	J01DC10 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	95%
Protein binding	36%
Elimination half-life	1.3 hours
Identifiers
	IUPAC name 7-[2-amino-2-(4-hydroxyphenyl)-acetyl]amino-8-oxo-3-prop-1-enyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;
CAS Number	92665-29-7 ;
PubChem CID	9887643;
DrugBank	DB01150 ;
ChemSpider	8063315 ;
UNII	1M698F4H4E;
KEGG	D07651 ;
ChEBI	CHEBI:3506 ;
ChEMBL	ChEMBL1742 ;
CompTox Dashboard (EPA)	DTXSID10873545 ;
Chemical and physical data
Formula	C18H19N3O5S
Molar mass	389.427 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N1/C(=C(/C=C/C)CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccc(O)cc3)N)C(=O)O.O;
	InChI InChI=1S/C18H19N3O5S.H2O/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9;/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26);1H2/b3-2-;/t12-,13-,17-;/m1./s1 ; Key:ALYUMNAHLSSTOU-HERYOFLYSA-N ;
	(what is this?) (verify)

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 08:13, 24 November 2015

Cefprozil, sometimes spelled cefproxil and marketed under the trade name Cefzil, is a second-generation cephalosporin type antibiotic. In Europe it is marketed using the trade names Procef and Cronocef.^{[citation needed]} It can be used to treat bronchitis, ear infections, skin infections, and other bacterial infections.^{[citation needed]} It comes as a tablet and as a liquid suspension.

Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article in the Journal of Family Practice^[1] has shown no increased risk for cross-allergy for cefprozil and several other second-generation or later cephalosporins.

Spectrum of bacterial susceptibility and resistance

Currently bacteria like Enterobacter aerogenes, Morganella morganii and Pseudomonas aeruginosa are resistant to Cefprozil, while Salmonella Agona and Streptococci are susceptible to Cefprozil. Some of the bacteria like Brucella abortus, Moraxella catarrhalis and Streptococcus pneumonia have developed resistance towards Cefprozil in varying degrees. For detailed minimum inhibition concentration information, please refer to Cefprozil Susceptibility and Resistance Data sheet.^[2]

Synthesis

Semisynthetic oral cephalosporin consisting of ~90:10 Z/E isomeric mixture.

Displacement of the allylic chloride in intermediate (1) with triphenylphosphine gives the phosphonium salt (2). This functionality is then converted to its ylide; condensation with acetaldehyde then leads to the vinyl derivative (3); deprotection then gives cefprozil.

References

^ Pichichero, ME (February 2006). "Cephalosporins can be prescribed safely for penicillin-allergic patients". J Fam Pract. 55 (2): 106–12. PMID 16451776.
^ "Cefprozil Susceptibility and Resistance Data" (PDF). Retrieved 23 July 2013.
^ H. Hoshi et al., DE 3402642 ; eidem, U.S. patent 4,520,022 (1984, 1985 both to Bristol-Myers).
^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 3624077, please use {{cite journal}} with |pmid=3624077 instead.
^ M. A. Kaplan et al., U.S. patent 4,727,070 (1988 to Bristol-Myers).

External links

Cefprozil MedlinePlus Drug Information

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

[1] Pichichero, ME (February 2006). "Cephalosporins can be prescribed safely for penicillin-allergic patients". J Fam Pract. 55 (2): 106–12. PMID 16451776.

[2] "Cefprozil Susceptibility and Resistance Data" (PDF). Retrieved 23 July 2013.

[3] H. Hoshi et al., DE 3402642 ; eidem, U.S. patent 4,520,022 (1984, 1985 both to Bristol-Myers).

[4] Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 3624077, please use {{cite journal}} with |pmid=3624077 instead.

[5] M. A. Kaplan et al., U.S. patent 4,727,070 (1988 to Bristol-Myers).

[1]

[2]

[3]

[4]

[5]

@@ Line 63: / Line 63: @@
 ==Synthesis==
 Semisynthetic oral cephalosporin consisting of ~90:10 Z/E isomeric mixture.
-[[File:Cefprozil synthesis.svg|thumb|center|700px|Cefprozil synthesis:<ref>H. Hoshi et al., {{Cite patent|DE|3402642}}; eidem, {{US patent|4520022}} (1984, 1985 both to [[Bristol-Myers]]).</ref><ref>{{Cite pmid|3624077}}</ref> Separation of isomers:<ref> M. A. Kaplan et al., {{US patent|4727070}} (1988 to [[Bristol-Myers]]).</ref>]]
+[[File:Cefprozil synthesis.svg|thumb|center|500px|Cefprozil synthesis:<ref>H. Hoshi et al., {{Cite patent|DE|3402642}}; eidem, {{US patent|4520022}} (1984, 1985 both to [[Bristol-Myers]]).</ref><ref>{{Cite pmid|3624077}}</ref> Separation of isomers:<ref> M. A. Kaplan et al., {{US patent|4727070}} (1988 to [[Bristol-Myers]]).</ref>]]
+Displacement of the allylic chloride in intermediate ('''1''') with [[triphenylphosphine]] gives the phosphonium salt ('''2'''). This functionality is then converted to its [[ylide]]; condensation with [[acetaldehyde]] then leads to the [[vinyl]] derivative ('''3'''); deprotection then gives cefprozil.
 ==References==
 {{reflist}}